Skip to main content
. 2017 Feb 14;174(6):438–453. doi: 10.1111/bph.13709

Figure 1.

Figure 1

Outline of the experimental protocols. Experimental Series 1. Hearts were perfused with an activator of both PKA and Epac (8‐Br, 5 μM), an inhibitor of PKA (H‐89) and Epac (ESI‐09). Groups of hearts: Control, 8‐Br, 8‐Br + H‐89 and 8‐Br + ESI‐09. Experimental Series 2. Hearts were perfused with 8‐Br (10 μM), a PKC inhibitor chelerythrine (Chel) and a specific PKA inhibitor peptide PKI. Groups of hearts: Control, 8‐Br, 8‐Br + PKI and 8‐Br + Chel. Experimental Series 3. Hearts were perfused with a PKA activator (6‐Bnz) and an Epac activator (CPT). Groups of hearts: Control, 6‐Bnz, CPT and 6‐Bnz + CPT.